Investigation of the human-gut-kidney axis by fecal proteomics, highlights molecular mechanisms affected in CKD.

4 illustrates a decreasing trend in AMY2A concentration from 89.37 ± 13.55 μg/mL in the CKD1 group to 37.40 ± 89.53 μg/mL in the CKD4 group, with a fold change (CKD4/CKD1) of 0.42, in line to the proteomics results.

also in 47,180 other papers